X4 Pharmaceuticals (XFOR) Non Operating Interest Expenses (2017 - 2026)

X4 Pharmaceuticals (XFOR) has reported Non Operating Interest Expenses for 10 consecutive years, with $2.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Non Operating Interest Expenses fell 3.05% year-over-year to $2.2 million; the trailing twelve-month figure through Jun 2026 stood at $8.7 million (down 4.48% YoY), and the FY2025 full-year result was $8.9 million, up 1.23% from the prior year.
• Non Operating Interest Expenses advanced to $2.2 million in Q2 2026 per XFOR's latest filing, from $2.1 million in the prior quarter.
• Across five years, Non Operating Interest Expenses topped out at $2.4 million in Q3 2024 and bottomed at $913000.0 in Q1 2022.
• Historically, Non Operating Interest Expenses has averaged $1.8 million across 5 years, with a median of $2.0 million in 2023.
• The sharpest annual moves came in 2024 and 2025: Non Operating Interest Expenses soared 89.55% in 2024, then declined 6.5% in 2025.
• Over 5 years, Non Operating Interest Expenses stood at $1.1 million in 2022, then jumped by 64.86% to $1.9 million in 2023, then rose by 22.16% to $2.3 million in 2024, then fell by 5.12% to $2.2 million in 2025, then retreated by 1.01% to $2.2 million in 2026.
• According to Business Quant data, Non Operating Interest Expenses over the past three periods registered $2.2 million, $2.1 million, and $2.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.